Article
Excerpt from the Press Release: SAN DIEGO and HONG KONG and SYDNEY, July 6, 2022 /PRNewswire/ — Inmagene Biopharmaceuticals (“Inmagene“) and HUTCHMED (China) Limited (“HUTCHMED“) (Nasdaq/AIM:HCM; HKEX:13) announces today that the first participant, based in Australia, was dosed in a global Phase I trial of IMG-007, an investigational OX40 antagonistic monoclonal antibody. The Phase I study…
Read More
IMM-BCP-01 neutralized BA.4/.5 and BA.2.12.1 subvariants in pseudovirus testing IMM-BCP-01 currently in Phase 1b clinical testing with topline data expected in 2H 2022 Excerpt from the Press Release: EXTON, Pa.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that…
Read More
The presented data show ELI-005 elicits strong and long-lasting cellular and humoral immune responses that were maintained at significantly higher levels than comparator vaccines over 32 weeks in mice. ELI-005, containing the lymph node-targeted Amphiphile vaccine adjuvant AMP-CpG, induced potent, comprehensive and persistent innate immune responses in draining lymph nodes in mice. Animals treated with…
Read More
AAVHSC16 Biodistribution Properties in Preclinical Models Demonstrated Potential for Systemic Delivery of Genetic Medicines to Brain, Heart and Muscle Excerpt from the Press Release: BEDFORD, Mass., July 05, 2022 (GLOBE NEWSWIRE) — Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the peer-reviewed publication of data showing that AAVHSC16, one of the capsids…
Read More
Excerpt from the Press Release: BOSTON, July 5, 2022 /PRNewswire/ — Unravel Biosciences, Inc. (“Unravel”), a therapeutics company that spun out from the Wyss Institute for Biologically Inspired Engineering at Harvard University, seamlessly bridges target discovery with clinical efficacy to advance drugs for complex diseases, today announced a partnership with TMA Precision Health (“TMA”), a…
Read More
Excerpt from the Press Release: SAN FRANCISCO and SUZHOU, China , July 3, 2022 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, autoimmune, metabolic, ophthalmology and other major diseases, announced that the first patient with moderate-to-severe active ulcerative colitis…
Read More
— Results Continue to Support that STAR-0215 is a Potent, Selective, and Long-Acting Monoclonal Antibody Inhibitor of Plasma Kallikrein — — STAR-0215 Demonstrates Rapid and Sustained Inhibition of Plasma Kallikrein After Subcutaneous Administration in Monkeys — Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and…
Read More
– REACH is the first Phase 3 trial for this rare, progressive, and debilitating muscular disease –– Losmapimod is an oral small molecule that has the potential to be the first therapy to treat FSHD, the second most common form of muscular dystrophy –– U.S. Food and Drug Administration (FDA) granted Fast Track Designation in 2021 –…
Read More
Study reveals first-ever structure of a non-viral endogenous reverse transcriptase (eRT) Human endogenous retrovirus-K (HERV-K) RT shows striking similarity to HIV RT Findings enable structure-based drug discovery for eRTs Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–ROME Therapeutics, a biotechnology company harnessing the power of the dark genome for drug development, today announced a new…
Read More
AN2 is developing epetraborole as a once-daily, orally administered treatment with a novel mechanism of action for patients with NTM lung disease, with an initial focus on treatment-refractory MAC lung disease Phase 2/3 pivotal trial expected to support regulatory approval for treatment-refractory MAC lung disease; Plan to use LPAD pathway Excerpt from the Press Release:…
Read More